Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31680358 | 1.00 | KDM4E (0.32) | KDM4E | |
| SCHEMBL283763 | 0.88 | — | — | |
| SCHEMBL18133132 | 0.88 | — | — | |
| SCHEMBL12292409 | 0.80 | PDK1 (0.32) | KDM4E | |
| SCHEMBL26031968 | 0.80 | PDK1 (0.32) | KDM4E | |
| SCHEMBL2045307 | 0.80 | KDM4E (0.32) | KDM4E | |
| SCHEMBL26025540 | 0.80 | PDK1 (0.32) | KDM4E | |
| SCHEMBL29899127 | 0.78 | CHRM2 (0.39) | — | |
| SCHEMBL7290346 | 0.77 | KDM4E (0.30) | KDM4E | |
| SCHEMBL30544792 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230032974-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2023-02-02 | — | — | US | disclosed |
| US-20220177885-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210228614-A1 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION | 2021-07-29 | — | — | US | disclosed |
| US-11034957-B2 | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200339991-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190330630-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190241893-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2019-08-08 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAF6, TRAF2, TNFRSF1A | KDM4E 3743/4885 |
| US-20200339991-A1 | AMYLOID PRECURSOR PROTEIN (APP) RNAi AGENT COMPOSITIONS AND METHODS OF USE THEREOF | APP, APBA1, PSEN1 | KDM4E 4411/4885 |
| US-20230032974-A1 | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | RPS25, RBM25, RPS26 | KDM4E 4115/4885 |
| US-11034957-B2 | Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof | APP, APBA1, PSEN1 | KDM4E 4411/4885 |
| US-20210228614-A1 | LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | LDHA, LDHB, HAO1 | KDM4E 4708/4885 |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | KDM4E 3902/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | KDM4E 4852/4885 |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | POLRMT, ACAT1, GPAA1 | KDM4E 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.